Your browser doesn't support javascript.
loading
Comparative B cell and antibody responses induced by adenoviral vectored and mRNA vaccines against COVID-19.
Liu, Yi; Sánchez-Ovando, Stephany; Carolan, Louise; Dowson, Leslie; Khvorov, Arseniy; Hadiprodjo, Jessica; Tseng, Yeu Yang; Delahunty, Catherine; Khatami, Ameneh; Macnish, Marion; Dougherty, Sonia; Hagenauer, Michelle; Riley, Kathryn E; Jadhav, Ajay; Harvey, Joanne; Kaiser, Marti; Mathew, Suja; Hodgson, David; Leung, Vivian; Subbarao, Kanta; Cheng, Allen C; Macartney, Kristine; Koirala, Archana; Marshall, Helen; Clark, Julia; Blyth, Christopher C; Wark, Peter; Kucharski, Adam J; Sullivan, Sheena G; Fox, Annette.
Afiliación
  • Liu Y; Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Sánchez-Ovando S; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Carolan L; Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Dowson L; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Khvorov A; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Hadiprodjo J; Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Tseng YY; Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Delahunty C; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Khatami A; Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Macnish M; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Dougherty S; Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Hagenauer M; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Riley KE; Immune Health Program, Hunter Medical Research Institute and School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
  • Jadhav A; The Children's Hospital at Westmead; Sydney Children's Hospital Network; National Centre for Immunisation Research and Surveillance, Sydney, Australia.
  • Harvey J; The University of Sydney; and National Centre for Immunisation Research and Surveillance, Sydney, Australia.
  • Kaiser M; Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
  • Mathew S; Queensland Children's Hospital, Children's Health Queensland Hospital and Health Service; and University of Queensland, Brisbane, Australia.
  • Hodgson D; Alfred Health and Monash University, Melbourne, Australia.
  • Leung V; Adelaide Medical School and Robinson Research Institute, The University of Adelaide, Adelaide, Australia.
  • Subbarao K; Division of Paediatric Medicine, Women's and Children's Health Network, Adelaide, Australia.
  • Cheng AC; The Children's Hospital at Westmead; Sydney Children's Hospital Network; National Centre for Immunisation Research and Surveillance, Sydney, Australia.
  • Macartney K; Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
  • Koirala A; Alfred Health and Monash University, Melbourne, Australia.
  • Marshall H; Adelaide Medical School and Robinson Research Institute, The University of Adelaide, Adelaide, Australia.
  • Clark J; Division of Paediatric Medicine, Women's and Children's Health Network, Adelaide, Australia.
  • Blyth CC; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
  • Wark P; Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Kucharski AJ; Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Sullivan SG; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Fox A; Alfred Health and Monash University, Melbourne, Australia.
medRxiv ; 2023 Jun 05.
Article en En | MEDLINE | ID: mdl-37333329
ABSTRACT
Both vector and mRNA vaccines were an important part of the response to the COVID-19 pandemic and may be required in future outbreaks and pandemics. However, adenoviral vectored (AdV) vaccines may be less immunogenic than mRNA vaccines against SARS-CoV-2. We assessed anti-spike and anti-vector immunity among infection-naïve Health Care Workers (HCW) following two doses of AdV (AZD1222) versus mRNA (BNT162b2) vaccine. 183 AdV and 274 mRNA vaccinees enrolled between April and October 2021. Median ages were 42 and 39 years, respectively. Blood was collected at least once, 10-48 days after vaccine dose 2. Surrogate virus neutralization test (sVNT) and spike binding antibody titres were a median of 4.2 and 2.2 times lower, respectively, for AdV compared to mRNA vaccinees (p<0.001). Median percentages of memory B cells that recognized fluorescent-tagged spike and RBD were 2.9 and 8.3 times lower, respectively for AdV compared to mRNA vaccinees. Titres of IgG reactive with human Adenovirus type 5 hexon protein rose a median of 2.2-fold after AdV vaccination but were not correlated with anti-spike antibody titres. Together the results show that mRNA induced substantially more sVNT antibody than AdV vaccine due to greater B cell expansion and targeting of the RBD. Pre-existing AdV vector cross-reactive antibodies were boosted following AdV vaccination but had no detectable effect on immunogenicity.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: MedRxiv Año: 2023 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: MedRxiv Año: 2023 Tipo del documento: Article País de afiliación: Australia